Abstract
A review deals with the problem of chronic kidney disease (CKD) from the position of a physician and cardiologist. The epidemiology of the disease was discussed both abroad and in Russia, including the most up-to-date data. In Russia CKD markers were detected in 49.4% of hypertensives. Authors describe risk factors and mechanisms of CKD at the most important pathogenetic conditions: hypertension, diabetes and obesity. The current classification and methods for calculating the glomerular filtration rate are given. The review disclose a paradigm of the renal continuum and its relation to cardiovascular diseases. It is well known fact that the final causes of the death of patients with CKD, as a rule, are cardiovascular complications. Based on the literature data, the necessity and expediency of screening for renal dysfunction is justified. In the example of use of an angiotensin receptor blocker II - irbesartan nephroprotective demonstrated possibilities of intervention in patients with renal dysfunction of varying severity.
Highlights
A review deals with the problem of chronic kidney disease (CKD) from the position of a physician and cardiologist
In Russia CKD markers were detected in 49.4% of hypertensives
The review disclose a paradigm of the renal continuum and its relation to cardiovascular diseases
Summary
ÔÃÀÎÓ ÂÎ «Ïåðâûé Ìîñêîâñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò èì. È.Ì. Ñå÷åíîâà» Ìèíçäðàâà Ðîññèè (Ñå÷åíîâñêèé Óíèâåðñèòåò), Ìîñêâà, Ðîññèÿ. Àííîòàöèÿ Ïðåäñòàâëåí îáçîð ëèòåðàòóðû ïî ïðîáëåìå õðîíè÷åñêîé áîëåçíè ïî÷åê (ÕÁÏ) ñ ïîçèöèé òåðàïåâòà è êàðäèîëîãà. Îáñóæäåíà ýïèäåìèîëîãèÿ çàáîëåâàíèÿ êàê çà ðóáåæîì, òàê è â Ðîññèè, â òîì ÷èñëå íà îñíîâàíèè íàèáîëåå ñîâðåìåííûõ äàííûõ 2017 ã.  Ðîññèè ìàðêåðû ÕÁÏ âûÿâëÿþòñÿ ó 49,4% ïàöèåíòîâ ñ àðòåðèàëüíîé ãèïåðòåíçèåé. Àâòîðàìè îïèñàíû ôàêòîðû ðèñêà è ìåõàíèçìû ðàçâèòèÿ ÕÁÏ ïðè íàèáîëåå çíà÷èìûõ ñ ïàòîãåíåòè÷åñêîé òî÷êè çðåíèÿ ñîñòîÿíèÿõ: àðòåðèàëüíîé ãèïåðòåíçèè, ñàõàðíîì äèàáåòå è îæèðåíèè. Èçâåñòíî, ÷òî íåïîñðåäñòâåííîé ïðè÷èíîé ãèáåëè ïàöèåíòîâ ñ ÕÁÏ, êàê ïðàâèëî, ÿâëÿþòñÿ ñåðäå÷íî-ñîñóäèñòûå îñëîæíåíèÿ. Íà îñíîâàíèè äàííûõ ëèòåðàòóðû îáîñíîâàíû íåîáõîäèìîñòü è öåëåñîîáðàçíîñòü ïðîâåäåíèÿ ñêðèíèíãà íàðóøåíèÿ ôóíêöèè ïî÷åê. Íà ïðèìåðå èñïîëüçîâàíèÿ áëîêàòîðà ðåöåïòîðîâ àíãèîòåíçèíà II èðáåñàðòàíà ïðîäåìîíñòðèðîâàíû âîçìîæíîñòè íåôðîïðîòåêòèâíîãî âìåøàòåëüñòâà ó ïàöèåíòîâ ñ äèñôóíêöèåé ïî÷åê ðàçíîé ñòåïåíè âûðàæåííîñòè. Êëþ÷åâûå ñëîâà: õðîíè÷åñêàÿ áîëåçíü ïî÷åê, ïî÷å÷íûé êîíòèíóóì, íåôðîïðîòåêöèÿ, áëîêàòîð ðåöåïòîðîâ àíãèîòåíçèíà II
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have